Published in Pathologe on July 01, 2017
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor antigens recognized by T cells. Immunol Today (1997) 2.28
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 2.27
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer (1995) 1.81
Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer (2000) 1.60
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun (2007) 1.46
Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer (2000) 1.34
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res (2006) 1.24
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer (2002) 1.17
Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother Emphasis Tumor Immunol (1993) 1.05
Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate (2006) 1.01
Vaccination for malignant melanoma: recent developments. Oncology (2001) 0.92
The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol (2012) 0.91
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One (2013) 0.86
Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Cancer (2016) 0.85
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res (2015) 0.82
Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw (2013) 0.81
MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. J Immunother (2016) 0.78
Pediatric Melanoma and Atypical Melanocytic Neoplasms. Cancer Treat Res (2016) 0.78
MAGE-A Antigens and Cancer Immunotherapy. Front Med (Lausanne) (2017) 0.78
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget (2017) 0.78
Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients. J Dermatol (2017) 0.77